



# The effect of high altitude (2500 m) on incremental cycling exercise in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a randomised controlled crossover trial

Julian Müller <sup>1,2,3</sup>, Anna Titz <sup>1,2,3</sup>, Simon R. Schneider <sup>1,2</sup>, Meret Bauer<sup>1,2</sup>, Laura Mayer<sup>1,2</sup>, Lea Lüönd<sup>1,2</sup>, Tanja Ulrich<sup>1,2</sup>, Michael Furian <sup>1,2</sup>, Aglaia Forrer<sup>1,2</sup>, Esther I. Schwarz<sup>1,2</sup>, Konrad E. Bloch<sup>1,2</sup>, Mona Lichtblau <sup>1,2</sup> and Silvia Ulrich <sup>1,2</sup>

<sup>1</sup>University Hospital of Zurich, Zurich, Switzerland. <sup>2</sup>University of Zurich, Zurich, Switzerland. <sup>3</sup>J. Müller and A. Titz contributed equally to this work.

Corresponding author: Silvia Ulrich ([silvia.ulrich@usz.ch](mailto:silvia.ulrich@usz.ch))



Shareable abstract (@ERSpublications)

In 27 patients with stable PVD, cycling exercise at 2500 m was well tolerated, but exercise capacity was lower compared with 470 m, associated with lower blood oxygenation and increased ventilatory inefficiency <https://bit.ly/47ryXTT>

**Cite this article as:** Müller J, Titz A, Schneider SR, *et al.* The effect of high altitude (2500 m) on incremental cycling exercise in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a randomised controlled crossover trial. *Eur Respir J* 2024; 63: 2301001 [DOI: 10.1183/13993003.01001-2023].

This extracted version can be shared freely online.

Copyright ©The authors 2024.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

This article has an editorial commentary:  
<https://doi.org/10.1183/13993003.00111-2024>

Received: 13 June 2023  
Accepted: 9 Jan 2024

## Abstract

**Background** Our objective was to investigate the effect of a day-long exposure to high altitude on peak exercise capacity and safety in stable patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

**Methods** In a randomised controlled crossover trial, stable patients with PAH or distal CTEPH without resting hypoxaemia at low altitude performed two incremental exercise tests to exhaustion: one after 3–5 h at high altitude (2500 m) and one at low altitude (470 m).

**Results** In 27 patients with PAH/CTEPH (44% females, mean±SD age 62±14 years), maximal work rate was 110±64 W at 2500 m and 123±64 W at 470 m (–11%, 95% CI –16– –11%; p<0.001). Oxygen saturation measured by pulse oximetry and arterial oxygen tension at end-exercise were 83±6% versus 91±6% and 6.1±1.9 versus 8.6±1.9 kPa (–8% and –29%; both p<0.001) at 2500 versus 470 m, respectively. Maximal oxygen uptake was 17.8±7.5 L·min<sup>-1</sup>·kg<sup>-1</sup> at high altitude versus 20±7.4 L·min<sup>-1</sup>·kg<sup>-1</sup> at low altitude (–11%; p<0.001). At end-exercise, the ventilatory equivalent for carbon dioxide was 43±9 at 2500 m versus 39±9 at 470 m (9%, 95% CI 2–6%; p=0.002). No adverse events occurred during or after exercise.

**Conclusions** Among predominantly low-risk patients with stable PAH/CTEPH, cycling exercise during the first day at 2500 m was well tolerated, but peak exercise capacity, blood oxygenation and ventilatory efficiency were lower compared with 470 m.

